The recommended solvents for the compound with the product number 1341001-200MG, which is a USP product, are organic solvents such as ethanol, DMSO, and dimethyl formamide. These solvents should be purged with an inert gas. The compound is soluble in water at 0.02 mg/ml and in a 45% w/v 2-Hydroxypropyl-β-cyclodextrin solution at 3.0 mg/ml.
For the storage conditions it is to be noted that the compound is air-sensitive and not stable in solution, thus, specific solution storage information is not available.
1341001
USP
Indomethacin
United States Pharmacopeia (USP) Reference Standard
Synonym(s):
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid
Sign Into View Organizational & Contract Pricing
All Photos(1)
Select a Size
Change View
200 MG
$868.00
About This Item
Empirical Formula (Hill Notation):
C19H16ClNO4
CAS Number:
Molecular Weight:
357.79
Beilstein:
497341
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
pharmaceutical primary standard
API family
indomethacin
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
COc1ccc2n(c(C)c(CC(O)=O)c2c1)C(=O)c3ccc(Cl)cc3
InChI
1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
InChI key
CGIGDMFJXJATDK-UHFFFAOYSA-N
Gene Information
human ... PTGS1(5742) , PTGS2(5743)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Indomethacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Indomethacin Capsules
- Indomethacin Extended-Release Capsules
- Indomethacin for Injection
- Indomethacin Oral Suspension
- Indomethacin Sodium
- Indomethacin Suppositories
Biochem/physiol Actions
Cyclooxygenase (COX) inhibitor that is relatively selective for COX-1.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 1 Oral
Storage Class Code
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Taco J Blokhuis et al.
Clinical orthopaedics and related research, 467(2), 526-530 (2008-09-30)
Heterotopic ossification is a well-known complication after fixation of an acetabular fracture. Indomethacin and radiation therapy are used as prophylaxis to prevent heterotopic ossification. It is unclear, however, whether either is superior, although this may relate to lack of power
Ramesh Chennupati et al.
PloS one, 9(7), e102264-e102264 (2014-07-18)
Argininosuccinate synthetase (ASS) is essential for recycling L-citrulline, the by-product of NO synthase (NOS), to the NOS substrate L-arginine. Here, we assessed whether disturbed arginine resynthesis modulates endothelium-dependent vasodilatation in normal and diabetic male mice. Endothelium-selective Ass-deficient mice (Assfl/fl/Tie2Cretg/- = Ass-KOTie2) were
L J Jones et al.
Archives of disease in childhood. Fetal and neonatal edition, 96(1), F45-F52 (2010-09-30)
To evaluate the effects of indomethacin or ibuprofen compared with placebo on closure, morbidity and mortality in preterm infants <37 weeks' gestation with echocardiographically and/or clinically important patent ductus arteriosus (PDA) at >24 h of life. MEDLINE, EMBASE, Cochrane Central
Brian J Krieg et al.
Journal of pharmaceutical sciences, 103(11), 3473-3490 (2014-09-13)
Development of an oral in vivo predictive dissolution medium for acid drugs with a pKa in the physiological range (e.g., Biopharmaceutics Classification System Class IIa) requires transport analysis of the complex in vivo CO2 /bicarbonate buffering system. In this report
Roland Neumann et al.
Neonatology, 102(1), 9-15 (2012-03-15)
Pharmacological closure of patent ductus arteriosus (PDA) is commonly achieved by intravenous (IV) administration of ibuprofen or indomethacin. Occasionally, oral ibuprofen is used for PDA treatment although its efficacy and safety are unclear. To systematically review randomized and quasi-randomized trials
-
What is the recommended solvent for the compound with the product number 1341001-200MG, and what are the storage conditions?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
